[go: up one dir, main page]

WO2009070921A1 - Médicament antidépresseur à base de matériaux d'amp cylique de jujube - Google Patents

Médicament antidépresseur à base de matériaux d'amp cylique de jujube Download PDF

Info

Publication number
WO2009070921A1
WO2009070921A1 PCT/CN2007/003397 CN2007003397W WO2009070921A1 WO 2009070921 A1 WO2009070921 A1 WO 2009070921A1 CN 2007003397 W CN2007003397 W CN 2007003397W WO 2009070921 A1 WO2009070921 A1 WO 2009070921A1
Authority
WO
WIPO (PCT)
Prior art keywords
jujube
extract
adenosine monophosphate
cyclic adenosine
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/003397
Other languages
English (en)
French (fr)
Inventor
Zuoguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200731299T priority Critical patent/SI2221058T1/sl
Priority to AU2007362023A priority patent/AU2007362023B2/en
Priority to MX2010005838A priority patent/MX2010005838A/es
Priority to US12/745,438 priority patent/US8889650B2/en
Priority to PL07845760T priority patent/PL2221058T3/pl
Priority to EP07845760.3A priority patent/EP2221058B1/en
Priority to HK11101715.9A priority patent/HK1147676B/zh
Priority to ES07845760T priority patent/ES2426351T3/es
Priority to DK07845760.3T priority patent/DK2221058T3/da
Priority to CA2707192A priority patent/CA2707192C/en
Priority to JP2010535191A priority patent/JP2011504885A/ja
Priority to BRPI0722181-9A priority patent/BRPI0722181A2/pt
Application filed by Individual filed Critical Individual
Priority to PCT/CN2007/003397 priority patent/WO2009070921A1/zh
Priority to KR1020107011900A priority patent/KR20100106324A/ko
Priority to PT78457603T priority patent/PT2221058E/pt
Publication of WO2009070921A1 publication Critical patent/WO2009070921A1/zh
Anticipated expiration legal-status Critical
Priority to ZA2010/04032A priority patent/ZA201004032B/en
Priority to CY20131100749T priority patent/CY1115223T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28078—Pore diameter
    • B01J20/28085—Pore diameter being more than 50 nm, i.e. macropores
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such

Definitions

  • the invention relates to a medicine or a health food for treating depression caused by jujube cyclic adenosine monophosphate (jujube cAMP).
  • the present invention also relates to a method for preparing a medicament for treating depression or a health food prepared by using jujube cAMP as a raw material. Background technique
  • Depression is a common disease. According to statistics, about 25% of women in the general population have experienced depression during their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology) . Data from the World Health Organization (WHO): The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that in the next 20 years, depression It will rise to the second most common disease in the world.
  • WHO World Health Organization
  • the antidepressant drugs are mainly based on Prozac, Serote, Zoloft, etc. (SSRI, SNRI, DRI, etc. 5HT, NE, DA reuptake inhibitors), and the mechanism of action is by increasing the human body.
  • the content of serotonin and other components in the nervous medium alleviates the symptoms of depression.
  • the object of the present invention is to provide a medicine or health food for treating depression caused by a raw material containing jujube cAMP, in particular, there are many side effects of the existing antidepressant medicine.
  • New technology solutions
  • Another object of the present invention is to provide a process for the preparation of a medicament for the treatment of depression or a health food prepared from the above-mentioned raw material containing jujube cAMP.
  • the solution of the medicament of the present invention is the result of my own research and exploration, combined with modern medical and pharmacological theories, especially in combination with adenylate cyclase (AC)-cyclic adenosine monophosphate (cAMP) signaling pathway, cAMP induces the transcription process and other research directions.
  • AC adenylate cyclase
  • cAMP adenosine monophosphate
  • the traditional Chinese medicine for treating depression has been deeply studied. After a large number of animal experiments, juvenile cAMP can be used as an exogenous non-hydrolyzed cAMP to participate in the metabolism of cAMP in the body. The hormonal effect increases the intracellular cAMP content, which is anti-depressant.
  • Jujube cAMP is obtained from the daily consumption of jujube fruits.
  • Jujube cAMP r source
  • ⁇ ⁇ j 3,, 5,-cyclic adenosine, 3,, 5, _ cyclic phosphate.
  • cAMP-like substance in jujube is very similar to that of cAMP. As an exogenous non-hydrolyzed cAMP, it can mimic the action of hormones and increase the intracellular cAMP content.
  • the present invention discloses an oral drug for treating depression, which is made from a raw material containing jujube cAMP.
  • the oral medicament of the present invention can be processed into any pharmacy such as a tablet, a capsule, a powder, a tablet, a powder, a solution, a microclay, a suspension, an emulsion, a granule, a pill, a pill, and the like.
  • Oral pharmaceutical dosage forms are well known.
  • the oral drug of the present invention is a daily dosage form, which is prepared from a raw material containing 0.003 to 0.3 mg of jujube cAMP; preferably, it is made of a raw material containing 0.01 to 0.25 g of jujube cAMP. to make.
  • the oral drug of the present invention is a dosage form which is administered twice a day, and is prepared from a raw material containing 0.002 to 0.2 mg of jujube cAMP; preferably, it is made of a raw material containing 0.005 0.12 mg of jujube cAMP. .
  • the oral drug of the present invention is a dosage form taken three times a day, which is prepared from a raw material containing 0.001 to 0.1 g of jujube cAMP; preferably, it is composed of 0.003 to 0.08 g of jujube Made from CAMP raw materials.
  • the oral drug of the present invention is a dosage form taken four times a day, and is prepared from a raw material containing 0.0008 to 0.06 mg of jujube cAMP; preferably, it is made of a raw material containing 0.002 to 0.04 mg of jujube cAMP. to make.
  • the present invention discloses a preparation method of an oral medicine for treating depression, which comprises pulverizing jujube and adding water at room temperature, and then extracting by water extraction and alcohol precipitation to obtain jujube extraction.
  • the liquid is further adsorbed and separated by two columns of macroporous resins OU-2 and ME-2, and dried to obtain jujube extract containing jujube cAMP of the present invention.
  • the oral medicament of the present invention may contain a pharmaceutically acceptable carrier or additive.
  • the oral medicament of the present invention can also be used to make health foods and nutrients.
  • the oral medicament for treating depression and the preparation method thereof according to the specification and the claims of the present invention are the core contents for realizing the object of the present invention, and after the disclosure of the present invention, those skilled in the art can according to the theory of Chinese medicine or related Modern pharmacological theory, the above-mentioned drugs are routinely flavored or replaced with other traditional Chinese medicine active ingredients with the same efficacy. Such conventional flavoring and replacement of other traditional Chinese medicines having similar or identical mechanisms of action or corresponding active ingredients are common technical activities of those skilled in the art and are therefore within the scope of protection of the present invention. Inside.
  • FIG. 1 is a schematic view showing the flow of a method for preparing a medicament of Example 1 of the present invention.
  • Fig. 2 is a flow chart showing the process of preparing the medicament of the embodiment 2 of the present invention.
  • Fig. 3 is a schematic flow chart showing the process of preparing the drug of the third embodiment of the present invention.
  • Fig. 4 is a flow chart showing the process of preparing the drug of the fourth embodiment of the present invention.
  • Fig. 5 is a flow chart showing the process of preparing the drug of the fifth embodiment of the present invention.
  • Fig. 6 is a flow chart showing the process of preparing the drug of the sixth embodiment of the present invention.
  • Figure 7 is a schematic flow chart showing the process of preparing the drug of Example 7 of the present invention. Preferred embodiment of the invention
  • the present invention is primarily directed to the preparation of the medicaments of the present invention in combination with the features of the present invention using methods known to those skilled in the art.
  • the following examples are for illustrative purposes only and are not intended to limit the invention.
  • the present invention particularly proposes the following technical solutions.
  • the raw material for treating depression is prepared by processing the raw material containing jujube cAMP.
  • the invention comprises the raw material containing jujube cAMP, and is processed into a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-dip, a suspension, an emulsion, a granule, and a drip for treating depression.
  • Oral pharmaceutical dosage forms well known in the art of pills, pills, and the like.
  • the medicament of the present invention is prepared in a dosage form containing 0.003 0.3 g of jujube cAMP, which is administered once a day; preferably, it is prepared from a raw material containing 0.01 to 0.25 g of jujube cAMP, once a day.
  • the medicament of the invention is prepared in a dosage form containing 0.003 0.3 g of jujube cAMP, which is administered once a day; preferably, it is prepared from a raw material containing 0.01 to 0.25 g of jujube cAMP, once a day.
  • the medicine of the present invention is prepared in a dosage form containing 0.002 to 0.2 g of jujube cAMP, which is administered twice a day; preferably, it is made from a raw material containing 0.005 to 0.12 mg of jujube cAMP.
  • the dosage form of the medicament of the invention is prepared in a dosage form containing 0.002 to 0.2 g of jujube cAMP, which is administered twice a day; preferably, it is made from a raw material containing 0.005 to 0.12 mg of jujube cAMP.
  • the drug of the present invention is prepared in a dosage form containing 0.0 (H ⁇ 0.1 mg jujube cAMP) in a dosage form taken three times a day; preferably, it is made from a raw material containing 0.003 to 0.08 mg of jujube cAMP, which is taken three times a day.
  • a dosage form of the medicament of the invention is prepared in a dosage form containing 0.0 (H ⁇ 0.1 mg jujube cAMP) in a dosage form taken three times a day; preferably, it is made from a raw material containing 0.003 to 0.08 mg of jujube cAMP, which is taken three times a day.
  • a dosage form of the medicament of the invention is prepared in a dosage form containing 0.0 (H ⁇ 0.1 mg jujube cAMP) in a dosage form taken three times a day; preferably, it is made from a raw material containing 0.003 to 0.08 mg of jujube cAMP, which is taken three times a
  • the medicine of the present invention is prepared in a dosage form containing 0.0008 to 0.06 g of jujube cAMP, and is preferably administered four times a day from a raw material containing 0.002 to 0.04 mg of jujube cAMP.
  • the dosage form of the medicament of the invention is prepared in a dosage form containing 0.0008 to 0.06 g of jujube cAMP, and is preferably administered four times a day from a raw material containing 0.002 to 0.04 mg of jujube cAMP.
  • the oral medicament of the present invention may contain a pharmaceutically acceptable carrier or additive.
  • the oral medicament of the present invention can also be used to make health foods and nutrients.
  • the raw material containing jujube cAMP is processed and prepared according to the method of Good Manufacturing Practice (GMP) to prepare an oral drug for treating depression.
  • GMP Good Manufacturing Practice
  • the raw material containing jujube cAMP is processed into a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-tank, and a suspension for treating depression in the present invention.
  • Oral pharmaceutical dosage forms well known in the art such as agents, emulsions, granules, pills, pills, and the like.
  • a raw material containing 0.003 to 0.3 mg of jujube cAMP is prepared into a dosage form of the present invention once daily; preferably, it is prepared from a raw material containing 0.01 to 0.25 g of jujube cAMP.
  • the medicament of the present invention is administered in a dosage form once daily.
  • a raw material containing 0.002 to 0.2 mg of jujube cAMP is prepared into a medicament of the present invention which is administered twice daily; preferably, it is prepared from a raw material containing 0.005 to 0.12 mg of jujube cAMP.
  • the medicament of the present invention is administered in a dosage form twice daily.
  • a raw material containing 0.001 to 0.1 mg of jujube cAMP is prepared into a dosage form of the present invention which is administered three times a day; preferably, it is prepared from a raw material containing 0.003 0.08 mg of jujube cAMP.
  • the drug of the present invention is administered in a dosage form three times a day.
  • a raw material containing 0.0008 to 0.06 mg of jujube cAMP is prepared into a dosage form of the present invention which is administered four times per EI; preferably, it is a raw material containing 0.002 to 0.04 g of jujube cAMP.
  • the medicament of the present invention is prepared in a dosage form which is administered four times a day.
  • the jujube is crushed, and then immersed in water at room temperature, and then extracted by water extraction and alcohol precipitation method to obtain jujube extract, and then the macroporous resin OU-2 and ME-2 are successively applied to the column for adsorption. Separation and drying were carried out to obtain a jujube extract containing a high concentration of jujube cAMP as a raw material for preparing the medicament of the present invention.
  • Method eight
  • jujube extract containing jujube cAMP and pharmaceutically acceptable carrier or additive are used as an oral drug for treating depression.
  • the raw material according to the present invention is processed into a health food for treating depression according to the method for producing and manufacturing a health food.
  • FIG. 1 is a schematic flow chart of a method for preparing the drug of the embodiment 1 of the present invention.
  • Fig. 1 according to the GMP pharmaceutical standard method, 30 g of jujube extract containing 1% jujube cAMP is prepared as raw material, and 270 g of starch, lactose, silica, magnesium stearate, etc. are added. Excipients and excipients, which are processed into a 10,000 tablet dosage form (30 mg/granule containing 0.03 mg of jujube cAMP), are oral or health foods for treating depression.
  • FIG. 2 is a schematic flow chart of a method for preparing the medicament of the embodiment 2 of the present invention.
  • 30 g of jujube extract containing 1% jujube cAMP is prepared as a raw material according to the GMP pharmaceutical standard method, and 420 g of starch, lactose, silica, magnesium stearate, etc. are added.
  • FIG. 3 is a schematic flow chart of a method for preparing the drug of Example 3 of the present invention.
  • 50 g of jujube extract containing 1% jujube cAMP is prepared as raw material, and 250 g of starch, lactose, silica, magnesium stearate and other excipients and excipients are added.
  • the present invention is processed into an oral or health food for treating depression in a 10,000 tablet dosage form (30 mg/granule containing 0.05 mg of jujube cAMP).
  • FIG. 4 is a schematic flow chart of a method for preparing the drug of the fourth embodiment of the present invention.
  • Fig. 4 according to the GMP pharmaceutical standard method, 30 g of jujube extract containing 1% jujube cAMP is prepared as raw material, and 210 g of starch, lactose, silica, magnesium stearate, etc. are added. Excipients and excipients, which were processed into a 12,000 tablet dosage form (20 mg/granule containing 0.25 mg of jujube cAMP), were used as an oral or health food for treating depression.
  • FIG. 5 a schematic flow chart of a method for preparing a medicament of Example 5 of the present invention.
  • 17 g of jujube extract containing 1% jujube cAMP is prepared as a raw material according to the GMP pharmaceutical standard method, and 183 g of starch, lactose, silica, stearic acid, etc. are added.
  • Excipients and excipients, which are processed into a 10,000 tablet dosage form (20 mg/granule containing 0.17 mg of jujube cAMP), are oral or health foods for treating depression.
  • FIG. 6 is a schematic flow chart of a method for preparing the drug of Example 6 of the present invention.
  • 13 g of jujube extract containing 1% jujube cAMP has been prepared as raw material, and 187 g of starch, lactose, silica, strontium stearate, etc. are added.
  • Excipients and excipients, which are processed into a 10,000 tablet dosage form (20 mg/granule containing 0.013 mg of jujube cAMP) are used in the treatment of oral medication or health food for depression.
  • FIG. 7 is a schematic flow chart of a method for preparing the drug of Example 7 of the present invention.
  • GMP The standard method of pharmacy, the 10 kg jujube is crushed, and then immersed in water at room temperature, and then extracted by water extraction and alcohol precipitation method to obtain jujube extract, and then the extract is successively treated with macroporous resin OU-2 and ME-2.
  • the upper column is adsorbed and separated, and dried to obtain 30 g of jujube extract containing jujube cAMP, which is detected by high performance liquid chromatography, and contains 1% (300 mg) of jujube cAMP for preparation of the present invention.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 3 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 3 Large dose: 5 mg/kg/d, medium dose: 2.5 mg/kg/d and small dose: 1.25 mg/kg/d.
  • mice were randomized into groups of 10: 1.
  • Example 3 high dose group (5 mg/kg, PO, 7d administration); 2.
  • Example 3 dose group (2.5 mg/kg, PO, administration) 7d); 3.
  • Example 3 low-dose group (1.25 mg/kg, PO, 7d); 4.
  • Paroxetine group (3 mg/kg, PO, 7d); 5.
  • Saline group (PO) A tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was suspended with a tape on a wooden strip 5 cm above the tabletop for 6 minutes, and the immobility time of the mouse within 5 minutes after recording was recorded.
  • Example 3 of the present invention has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 3 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 3 Large dose: 5 mg/kg/d, medium dose: 2.5 mg/kg/d, small dose: 1.25 mg/kg/d.
  • mice were randomized into groups of 10: 1.
  • Example 3 high dose group (5 mg/kg, PO, 7d administration); 2.
  • Example 3 dose group (2.5 mg/kg, PO, administration) 7d); 3.
  • Example 3 low-dose group (1.25 mg/kg, PO, 7d); 4.
  • Paroxetine group (3 mg/kg, PO, 7d); 5.
  • Saline group (PO) The mice were randomized into groups of 10: 1.
  • Example 3 high dose group (5 mg/kg, PO, 7d administration); 2.
  • Example 3 dose group (2.5 mg/kg, PO, administration) 7d); 3.
  • Example 3 low-dose group (1.25 mg/kg, PO, 7d);
  • Paroxetine group (3 mg/kg, PO, 7d); 5.
  • Saline group (PO) 5 mg/kg, PO, 7d administration
  • mice were placed in a glass jar having a water depth of 10 cm and a diameter of 20 cm at a water temperature of 25 ° C, and the cumulative time of the mice in the water was recorded for 5 minutes.
  • Example 3 of the present invention has an anti-sexual depression function.
  • the oral drug for treating depression according to the present invention may contain a pharmaceutically acceptable additive
  • the oral medicament for treating depression according to the present invention can be processed into various known dosage forms such as powders, capsules, tablets, and the like;
  • the oral medicament for treating depression according to the present invention can be formulated into a health food for treating depression.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Description

以大枣 CAMP为原料制成的抗忧郁药物
技术领域
本发明涉及一种以大枣环磷酸腺苷 （ 大枣 cyclic adenosine monophosphate, 大枣 cAMP )为原料制成的用于治疗忧郁症的药物或保健食 品。本发明还涉及一种以大枣 cAMP为原料制成的用于治疗忧郁症的药物或 保健食品的制备方法。 背景技术
忧郁症是一种常见的疾病，据统计在一般人口中大约有 25%女性在其一 生中经历过忧郁症， 男性中约有 10%左右经历过忧郁症（张春兴著： 《现代 心理学》 ） 。 世界卫生组织 （WHO )提供的数据： 忧郁症在全世界的发病 率约为 11%, 目前全球约有 3.4亿精神忧郁患者， 而且这个数字仍呈上升趋 势， 调查发现在今后 20年， 忧郁症将会上升为全球第二大常见疾病。
现有技术中， 抗忧郁药物以百忧解、 赛洛特、 左洛复等（SSRI、 SNRI、 DRI等类的 5HT、 NE、 DA再摄取抑制剂）为主， 其作用机制是通过增加 人体神经介质内 5-羟色胺等成分含量緩解忧郁症状。
但是， 这些药物都有不同程度的副作用， 例如： 增加自杀率、 头痛、 头 暈、 晕眩、 失眠、 嗜睡、 耳鸣、 口干、 厌食、 食欲增加、 体重上升、 血压上 升、 肠胃不适、 反胃、 恶心、 呕吐、 消化不良、 腹泻、 便秘、 下肢痛、 皮肤 出疹、 颤抖、 痉挛、 多汗、 水肿、 性欲降低、 性无能等。 近年来百忧解等抗 忧郁药物已成为社会严重关注的问题， 美国食品暨药物管理局 （Food and Drug Administration, FDA )更于 2004年要求药厂将市场上主要的 32种抗忧 郁药物重新标示其副作用和警告的部分，并对医护人员强调这些药物可能增 加孩童及青少年自杀的机率。 其中， 赛洛特更是早在 1996年就被发现存在 有安全隐患， 自 2001年开始已陆续从市场上召回。 2004年 6月， 美国紐约 州总检察长指控英国葛兰素史克公司为了获取利润 ,欺骗性隐瞒了服用赛洛 特与"增加青少年自杀倾向及行为的风险 "之间有关联的研究报告。在这种背 景下，如何研发生产新一代副作用低又能有明显抗忧郁作用的药物已成为全 球医药界所关注的问题。
因此， 申请人鉴于已知技术中所产生的不足， 经悉心研究与探索， 并本 着锲而不舍的精神，终构思出本发明的 r以大枣 cAMP为原料制成的抗忧郁 药物及其制法』 ， 以下为本发明的简要说明。 发明内容
为了克服现有技术的不足，本发明的目的在于提供一种以含大枣 cAMP 的原料制成的用于治疗忧郁症的药物或保健食品，特别是不会出现现有抗忧 郁药物诸多副作用的新技术方案。
本发明的另一目的是提供上述以含大枣 cAMP 的原料制成的用于治疗 忧郁症的药物或保健食品的制备方法。
本发明药物的解决方案是经本人潜心研究探索的结果，结合现代医学和 药理学理论， 特别是结合腺苷酸环化酶（adenylate cyclase, AC ) -环磷酸腺 苷（cAMP )信号传导通路、 cAMP诱导转录过程等研究方向， 对传统治疗 忧郁症的中药材进行了深入研究， 经过大量的动物试验证明： 大枣 cAMP 作为外源性非水解类 cAMP能参与机体中 cAMP的代谢过程， 可模拟激素 作用， 使得细胞内 cAMP含量增高， 从而起到抗忧郁功效。 大枣 cAMP是 从日常食用的水果大枣中提取而得，在人类长期日常食用和作为药材在中药 长期临床使用过程中，未出现因服用大枣而发生现有抗忧郁药物诸多副作用 的不良反应案例，发明人将含极微（约万分之一）大枣 cAMP的大枣用水提 取后， 更进一步将大枣水提取物纯化成含 1%大枣 cAMP的大枣提取物后， 进行抗试验性抑郁作用动物试验的结果显示， 具有明显的抗试验性抑郁功 能， 而未进一步纯化提高大枣 cAMP浓度的大枣水提取物， 虽然含有微量的 大枣 cAMP, 但以常规的药物剂量进行抗试验性抑郁作用动物试验时， 则不 具明显的抗试验性抑郁功能，故发明人提出以大枣 cAMP为原料制备成用于 治疗忧郁症药物的新技术方案以改进已知技术中所产生的不足。
大枣 cAMP: r来源」 ： 鼠李科植物枣 Zizyphus jujuba Mill的干燥成熟果实。
Γ异名 j ： 3，，5，-环状腺苷酸， 3，,5，_环磷酸。
r英文名」 ： Cyclic adenosine-3，, 5 '-monophosphate
r分子式及相对分子量 j ： ( 1(3Η13Ν506Ρ·Η20, 347.23。
r生物活性」： 大枣中 cAMP样物质的活性与 cAMP非常相似， 作为外 源性非水解类 cAMP , 能模拟激素作用， 使得细胞内 cAMP含量增高。
r结构式 J ：
Figure imgf000005_0001
本发明揭露了一种用于治疗忧郁症的口服药物， 它是由包含大枣 cAMP 的原料所制成。
优选地， 本发明的口服药物可以加工制成锭剂、 胶嚢剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬剂、 乳剂、 颗粒剂、 滴丸剂、 丸剂等任何药剂 学上所公知的口服药物剂型。
优选地， 本发明的口服药物为每日服用一次的剂型， 是由包含 0.003 ~ 0.3 毫克大枣 cAMP 的原料所制成； 优选地， 是由含 0.01 ~ 0.25 亳克大枣 cAMP的原料所制成。
优选地， 本发明的口服药物为每日服用二次的剂型， 是由包含 0.002 ~ 0.2毫克大枣 cAMP的原料所制成； 优选地， 是由含 0.005 0.12毫克大枣 cAMP的原料所制成。
优选地， 本发明的口服药物为每日服用三次的剂型， 是由包含 0.001 ~ 0.1亳克大枣 cAMP的原料所制成； 优选地， 是由含 0.003 ~ 0.08亳克大枣 CAMP的原料所制成。
优选地， 本发明的口服药物为每日服用四次的剂型， 是由包含 0.0008 ~ 0.06毫克大枣 cAMP的原料所制成； 优选地， 是由含 0.002 ~ 0.04毫克大枣 cAMP的原料所制成。
根据本发明的另一方面，本发明揭露了一种用于治疗忧郁症的口服药物 的制备方法， 它是将大枣破碎后加水常温浸泡， 再以水提醇沉法提取， 得大 枣提取液， 再用大孔树脂 OU-2、 ME-2两柱连续上柱吸附分离， 干燥， 得本 发明含大枣 cAMP的大枣提取物。
优选地， 本发明的口服药物可以含有药学上可接受的载体或添加剂。 优选地， 本发明的口服药物还可用来制成保健食品和营养剂。
本发明说明书和权利要求中所述的用于治疗忧郁症的口服药物及其制 备方法， 是实现本发明目的的核心内容， 在本发明公开后， 本领域的技术人 员可以根据中医理论或是相关现代药理学理论，对上述药物进行常规的加味 化裁或是用功效作用相同的其它中药有效成分替代。这种常规的加味化裁和 作用机理相似或相同的其它的中药或是相应的有效成分来替代，均属于本领 域技术和研究人员的一般性技术活动， 故其都在本发明的保护范围之内。
本发明通过参阅附图及详细说明而获较佳了解。 附图概述
图 1为制备本发明实施例 1药物的方法流程示意图。
图 2为制备本发明实施例 2药物的方法流程示意图。
图 3为制备本发明实施例 3药物的方法流程示意图。
图 4为制备本发明实施例 4药物的方法流程示意图。
图 5为制备本发明实施例 5药物的方法流程示意图。
图 6为制备本发明实施例 6药物的方法流程示意图。
图 7为制备本发明实施例 7药物的方法流程示意图。 本发明的较佳实施方式
以下将结合附图和实施例进一步说明本发明。本发明主要是采用本领域 技术人员已知的方法结合本发明的特征制备本发明所述的药物。以下实施例 仅仅是为了说明， 并非限定本发明。
为了完成本发明的目的， 本发明特别提出下面技术方案。
方案一：
. 以含大枣 cAMP的原料， 加工制成本发明用于治疗忧郁症的口服药物。
方案二：
以含大枣 cAMP的原料，加工制成本发明用于治疗忧郁症的锭剂、胶嚢 剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬剂、 乳剂、 颗粒剂、 滴丸剂、 丸剂等任何药剂学上所公知的口服药物剂型。
""^^— - ·
以含 0.003 0.3亳克大枣 cAMP的原料，制成每日服用一次的剂型的本 发明药物； 优选地， 是由含 0.01 ~ 0.25亳克大枣 cAMP的原料， 制成每日服 用一次的剂型的本发明药物。
方案四：
以含 0.002 ~ 0.2亳克大枣 cAMP的原料，制成每日服用二次的剂型的本 发明药物； 优选地， 是由含 0.005 ~ 0.12毫克大枣 cAMP的原料， 制成每曰 服用二次的剂型的本发明药物。
方案五：
以含 0.0(H ~ 0.1毫克大枣 cAMP的原料，制成每日服用三次的剂型的本 发明药物； 优选地， 是由含 0.003 ~ 0.08毫克大枣 cAMP的原料， 制成每日 服用三次的剂型的本发明药物。 方案六：
以含 0.0008 ~ 0.06亳克大枣 cAMP的原料，制成每曰服用四次的剂型的 本发明药物； 优选地， 是由含 0.002 ~ 0.04毫克大枣 cAMP的原料， 制成每 日服用四次的剂型的本发明药物。
方案七. - 将大枣破碎后加水常温浸泡， 再以水提醇沉法提取， 得大枣提取物， 再 将该提取物用大孔树脂 OU-2、 ME-2两柱先后连续上柱吸附分离， 干燥， 得 含高浓度大枣 cAMP的大枣提取物作为原料供制备本发明药物。
方案八：
本发明的口服药物可以含有药学上可接受的载体或添加剂。
方案九：
本发明的口服药物还可用来制成保健食品和营养剂。
为了完成本发明的目的， 特提出以下药物的制作方法。
方法一：
依良好药品生产质量管理规范 （ Good Manufacturing Practice, GMP )制 药标准的方法，将含大枣 cAMP的原料，加工制备成本发明用于治疗忧郁症 的口服药物。
方法二：
依 GMP制药标准的方法， 将含大枣 cAMP的原料， 加工制成本发明用 于治疗忧郁症的锭剂、 胶嚢剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬 剂、 乳剂、 颗粒剂、 滴丸剂、 丸剂等任何药剂学上所公知的口服药物剂型。
方法三：
依 GMP制药标准的方法， 将含 0.003 ~ 0.3毫克大枣 cAMP的原料， 制 备成每日服用一次的剂型的本发明药物； 优选地， 是由含 0.01 ~ 0.25亳克大 枣 cAMP的原料， 制备成每日服用一次的剂型的本发明药物。
方法四：
依 GMP制药标准的方法， 将含 0.002 ~ 0.2毫克大枣 cAMP的原料， 制 备成每日服用二次的剂型的本发明药物； 优选地， 是由含 0.005 ~ 0.12毫克 大枣 cAMP的原料， 制备成每日服用二次的剂型的本发明药物。
方法五：
依 GMP制药标准的方法， 将含 0.001 ~ 0.1毫克大枣 cAMP的原料， 制 备成每日服用三次的剂型的本发明药物； 优选地， 是由含 0.003 0.08毫克 大枣 cAMP的原料， 制备成每日服用三次的剂型的本发明药物。
方法六：
依 GMP制药标准的方法， 将含 0.0008 ~ 0.06毫克大枣 cAMP的原料， 制备成每 EI服用四次的剂型的本发明药物； 优选地， 是由含 0.002 ~ 0.04亳 克大枣 cAMP的原料， 制备成每日服用四次的剂型的本发明药物。
方法七：
依 GMP制药标准的方法， 将大枣破碎后加水常温浸泡， 再以水提醇沉 法提取， 得大枣提取液， 再用大孔树脂 OU-2、 ME-2两柱先后连续上柱吸附 分离， 干燥，得含高浓度大枣 cAMP的大枣提取物作为原料供制备本发明药 物。 方法八：
依 GMP制药标准的方法， 将含大枣 cAMP的大枣提取物与药学上可接 受的载体或添加剂等原料， 制成本发明用于治疗忧郁症的口服药物。
方法九：
将本发明所述的原料依保健食品生产制造标准的方法，加工制成本发明 用于治疗忧郁症的保健食品。
具体实施例
以下将结合附图和具体实施案例进一步说明本发明。
实施例 1
请参阅图 1，为制备本发明实施例 1药物的方法流程示意图。在图 1中， 依 GMP制药标准的方法， 将已制备成含 1%大枣 cAMP的大枣提取物 30 g 为原料， 加上 270 g的淀粉、 乳糖、 二氧化硅、 硬酯酸镁等辅料及赋形剂， 加工制成 10,000粒锭剂型 （ 30 mg/粒， 内含 0.03 mg的大枣 cAMP ) 的本发 明用于治疗忧郁症的口服药物或保健食品。
实施例 2
请参阅图 2,为制备本发明实施例 2药物的方法流程示意图。在图 2中， 依 GMP制药标准的方法， 将已制备成含 1%大枣 cAMP的大枣提取物 30 g 为原料， 加上 420 g的淀粉、 乳糖、 二氧化硅、 硬酯酸镁等辅料及赋形剂， 加工制成 15，000粒锭剂型 （30 mg/粒， 内含 0.02 mg的大枣 cAMP ) 的本发 明用于治疗忧郁症的口服药物或保健食品。
实施例 3
请参阅图 3，为制备本发明实施例 3药物的方法流程示意图。在图 3中， 依 GMP制药标准的方法， 将已制备成含 1%大枣 cAMP的大枣提取物 50 g 为原料， 加上 250 g的淀粉、 乳糖、 二氧化硅、 硬酯酸镁等辅料及赋形剂， 加工制成 10,000粒锭剂型 （ 30 mg/粒， 内含 0.05 mg的大枣 cAMP ) 的本发 明用于治疗忧郁症的口服药物或保健食品。
实施例 4
请参阅图 4,为制备本发明实施例 4药物的方法流程示意图。在图 4中， 依 GMP制药标准的方法， 将已制备成含 1%大枣 cAMP的大枣提取物 30 g 为原料， 加上 210 g的淀粉、 乳糖、 二氧化硅、 硬酯酸镁等辅料及赋形剂， 加工制成 12,000粒锭剂型 （ 20 mg/粒， 内含 0.25 mg的大枣 cAMP ) 的本发 明用于治疗忧郁症的口服药物或保健食品。
实施例 5
' 请参阅图 5,为制备本发明实施例 5药物的方法流程示意图。在图 5中， 依 GMP制药标准的方法， 将已制备成含 1%大枣 cAMP的大枣提取物 17 g 为原料， 加上 183 g的淀粉、 乳糖、 二氧化硅、 硬酯酸棋等辅料及赋形剂， 加工制成 10,000粒锭剂型 （20 mg/粒， 内含 0.17 mg的大枣 cAMP ) 的本发 明用于治疗忧郁症的口服药物或保健食品。
实施例 6
请参阅图 6,为制备本发明实施例 6药物的方法流程示意图。在图 6中， 依 GMP制药标准的方法， 将已制备成含 1%大枣 cAMP的大枣提取物 13 g 为原料， 加上 187 g的淀粉、 乳糖、 二氧化硅、 硬酯酸镬等辅料及赋形剂， 加工制成 10,000粒锭剂型（ 20 mg/粒， 内含 0.013 mg的大枣 cAMP )的本发 明用于治疗忧郁症的口服药物或保健食品。
实施例 7
请参阅图 7, 为制备本发明实施例 7药物的方法流程示意图。 依 GMP 制药标准的方法，将 10 kg大枣破碎后加水常温浸泡，再以水提醇沉法提取， 得大枣提取物，再将该提取物用大孔树脂 OU-2、 ME-2两柱先后连续上柱吸 附分离， 干燥， 得 30 g含大枣 cAMP的大枣提取物， 经高效液相仪器检测， 该提取物中含有 1% ( 300 mg )的大枣 cAMP, 以供备制本发明用于治疗忧 郁症的口服药物或保健食品。
实验例 1
实施例 3对小鼠悬尾实验的影响
1.1 实瞼动物
ICR小鼠， 雄性， 体重 22.0±2 g, 二级， 北京首都医科大学实验动物科 学部提供。
1.2 实验药品
实施例 3: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀（赛乐特） ： 中美天津史克制药有限公司产品。
1.3 实验仪器： 秒表
1.4 剂量设计
实施例 3大剂量： 5 mg/kg/d、中剂量： 2.5 mg/kg/d及小剂量： 1.25 mg/kg/d。
1.5 实验方法及结杲
1.5.1 分组给药
将小鼠随机分组， 每组 10只： 1.实施例 3大剂量组（5 mg/kg, PO, 给 药 7d ) ； 2.实施例 3中剂量組（2.5 mg/kg, PO, 给药 7d ) ； 3.实施例 3小 剂量组 （1.25 mg/kg, PO, 给药 7d ) ； 4.帕罗西汀组（3 mg/kg, PO, 给药 7d ) ； 5.生理盐水组（PO ) 。 最后一次给药后 1小时进行悬尾实验。
1.5.2 实臉方法
将小鼠尾（距尾尖 1 cm处）用胶布粘在头高于台面 5 cm的木条上悬吊 6分钟， 记录后 5分钟内小鼠的不动时间。
1.5.3 统计学处理 实验资料用 ± S£)表示，实验结果用 SPSS 11.5统计软件进行方差分析。
1.5.4 实验结果
实验结果请参阅表 1。
表 1、 实施例 3对小鼠不动时间的影响
组 另) j 动物数（只） 不动时间 （秒） 生理盐水组（模型组） 10 122.18士 45.78 帕罗西汀组 10 67.59±39.09** 实施例 3大剂量组 10 75.13±38.26** 实施例 3中剂量组 10 86.80±48.08* 实施例 3小剂量组 10 102.36±13.68 注： 与模型组比较 * P<0.05 **P<0.01
结论：
根据以上实验， 可以看出本发明实施例 3大、 中剂量组和帕罗西汀组均 可减少小鼠悬尾后的不动时间， 且与生理盐水组（模型组）相比有显著性差 异， 从而可以推断本发明实施例 3具有抗实验性抑郁功能。
实验例 2
实施例 3对小鼠强迫游泳实验的影响
2.1 实验动物
ICR小鼠， 雄性， 体重 22.0±2 g, 二级， 北京首都医科大学实验动物科 学部提供。
2.2 实验药品
实施例 3: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀（赛乐特） ： 中美天津史克制药有限公司产品。
2.3 实臉仪器
秒表。 2.4 剂量设计
实施例 3大剂量： 5 mg/kg/d,中剂量： 2.5 mg/kg/d,小剂量： 1.25 mg/kg/d。
2.5 实验方法及结果
2.5.1 分组给药
将小鼠随机分组， 每组 10只： 1.实施例 3大剂量组（5 mg/kg, PO, 给 药 7d ) ； 2.实施例 3中剂量组（2.5 mg/kg, PO, 给药 7d ) ； 3.实施例 3小 剂量组（ 1.25 mg/kg, PO, 给药 7d ) ； 4.帕罗西汀组 （3 mg/kg, PO, 给药 7d ) ； 5.生理盐水组（PO ) 。
2.5.2 实验方法
小鼠末次给药 1小时后， 将小鼠分别放入水深 10 cm、 直径 20 cm的玻 璃缸中， 水温 25°C , 观察 5分钟记录小鼠在水中的累积不动时间。
2.5.3 统计学处理
实验资料用 士 SD表示,实验结果用 SPSS 11.5统计软件进行方差分析。 2.5.4 实验结果
. 实验结果请参阅表 2。
表 2、 实施例 3对小鼠强迫游泳实验的影响
组 另 ij 动物数（只） 不动时间 （秒） 生理盐水组（模型组） 10 127.53±41.80 帕罗西汀组 10 83.42d=40.71* 实施例 3大剂量组 10 80.39±40.89* 实施例 3中剂量组 10 87.60±43.42 实施例 3小剂量组 10 91.05±47.21 注： 与模型组比较 * P<0.05 **P<0.01
结论：
根据以上实验，可以看出本发明实施例 3大剂量组和帕罗西汀组均可明 显减少小鼠强迫游泳的不动时间，从而可以推断本发明实施例 3具有抗实驺 性抑郁功能。
工业实用性 本发明用于治疗忧郁症的口服药物的应用范围：
1.本发明所述的用于治疗忧郁症的口服药物中， 可以含有药物学上可接 受的添加剂；
2.本发明所述的用于治疗忧郁症的口服药物可以将其加工制成散剂、 胶 嚢剂、 片剂、 等各种已知的剂型； 以及
3.本发明所述的用于治疗忧郁症的口服药物可以制成用于治疗忧郁症 的保健食品。
本发明可由本领域技术人员进行各种改变，但都不脱离所附权利要求所 要求保护的范围。

Claims

权 刺 要 求 书
1. 一种治疗忧郁症的药物， 其为由含大枣环磷酸腺苷的原料制成的口 服药物。
2. 如权利要求 1 所述的药物， 其中所述含大枣环磷酸腺苷的原料是由 提取大枣获得第一提取物， 再純化所述第一提取物得第二提取物， 其中所述 第二提取物的大枣环磷酸腺苷浓度高于所述第一提取物的大枣环磷酸腺苷 浓度。
3. 如权利要求 1 所述的药物， 其中所述药物制成剂型， 所述剂型选自 锭剂、 胶嚢剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬剂、 乳剂、 颗粒 剂、 滴丸剂、 丸剂及药剂学上的口服药物剂型中的任一种。
4. 如权利要求 3 所述的药物， 其制成每日服用一次的剂型， 其中所述 剂型是由含 0.003 ~ 0.3毫克的大枣环碑 腺苷的原料所制成。
5. 如权利要求 4所述的药物， 其中所述剂型是由含 0.01 ~ 0.25毫克的 大枣环磷酸腺苷的原料所制成。
6. 如权利要求 3 所述的药物， 其制成每日服用二次的剂型， 其中所述 剂型是由含 0.002 ~ 0.2毫克的大枣环磷酸腺苷的原料所制成。
7. 如权利要求 6所述的药物， 其中所述剂型是由含 0.005 ~ 0.12毫克的 大枣环磷酸腺苷的原料所制成。
8. 如权利要求 3 所述的药物， 其制成每日服用三次的剂型， 其中所述 剂型是由含 0.001 - 0.1亳克的大枣环磷酸腺苷的原料所制成。
9. 如权利要求 8所述的药物， 其中所述剂型是由含 0.003 ~ 0.08亳克的 大枣环磷酸腺苷的原料所制成。
10. 如权利要求 3所述的药物， 其制成每日服用四次的剂型， 其中所述 剂型是由含 0.0008 ~ 0.06毫克的大枣环磷酸腺苷的原料所制成。
11. 如权利要求 10所述的药物， 其中所述剂型是由含 0.002 ~ 0.04亳克 的大枣环磷酸腺苷的原料所制成。
12. 如权利要求 1所述的药物，其中所述药物含有药学上可接受的载体、 添加剂或其组合。
13. 如权利要求 1所述的药物， 其中所述药物制成保健食品或营养剂。
14. 一种治疗忧郁症的药物的制备方法， 其包括下列步驟：
(a)提取大枣获得第一提取物； 及
(b)纯化所述第一提取物获得第二提取物，
其中所述第二提取物的大枣环磷酸腺苷浓度高于所述第一提取物的大 枣环磷酸腺苷浓度。
15. 如权利要求 14所述的制备方法， 其中步骤 (b)选用含醛基的大孔树 脂上柱吸附分离所述第一提取物中的大枣环磷酸腺苷。
16. 如权利要求 15所述的制备方法， 其中步骤 (b)选用含 基的大孔树 月旨 OU-2上柱吸附分离所述第一提取物中的大枣环磷酸腺苷。
17. 如权利要求 15所述的制备方法，其中步骤 (b)再以大孔树脂 ME2上 柱分离所述第一提取物中的大枣环磷酸腺苷。
18. 一种大枣环磷酸腺苷的制备方法， 其包括下列步骤：
(a)提取大枣获得第一提取物； 及
(b)纯化所述第一提取物获得第二提取物，且所述第二提取物的大枣环磷 酸腺苷浓度高于所述第一提取物的大枣环磷酸腺苷浓度。
其中步驟 (b)选用含醛基的大孔树脂上柱吸附分离所述第一提取物中的 大枣环磷酸腺苷。
19. 如权利要求 18所述的制备方法， 其中步骤 (b)选用含醛基的大孔树 脂 OU-2上柱吸附分离所述第一提取物中的大枣环磷酸腺苷。
20. 如权利要求 18所述的制备方法， 其中步骤 (b)再以大孔树脂 ME-2 上柱分离所述第一提取物中的大枣环磷酸腺苷。
PCT/CN2007/003397 2007-11-30 2007-11-30 Médicament antidépresseur à base de matériaux d'amp cylique de jujube Ceased WO2009070921A1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP2010535191A JP2011504885A (ja) 2007-11-30 2007-11-30 棗の環状アデノシン一リン酸から調製された抗うつ薬
MX2010005838A MX2010005838A (es) 2007-11-30 2007-11-30 Medicina antimelancolica preparada con materiales de camp de azufaifa.
US12/745,438 US8889650B2 (en) 2007-11-30 2007-11-30 Antimelancholic medicine prepared with jujube camp materials
PL07845760T PL2221058T3 (pl) 2007-11-30 2007-11-30 Lek przeciwko melancholii wytworzony z materiałów z cAMP z jujuba
EP07845760.3A EP2221058B1 (en) 2007-11-30 2007-11-30 Antimelancholic medicine prepared with jujube camp materials
HK11101715.9A HK1147676B (zh) 2007-11-30 以大枣camp为原料制成的抗忧郁药物及其制法
ES07845760T ES2426351T3 (es) 2007-11-30 2007-11-30 Medicina anti-melancolía preparada con materiales de cAMP de jujuba
DK07845760.3T DK2221058T3 (da) 2007-11-30 2007-11-30 Antidepressivt lægemiddel fremstillet med jujube cAMP stoffer
CA2707192A CA2707192C (en) 2007-11-30 2007-11-30 Antimelancholic medicine prepared with jujube camp materials
SI200731299T SI2221058T1 (sl) 2007-11-30 2007-11-30 Zdravilo proti melanholiji pripravljeno iz materialov jujuba cAMP
AU2007362023A AU2007362023B2 (en) 2007-11-30 2007-11-30 Antimelancholic medicine prepared with jujube camp materials
BRPI0722181-9A BRPI0722181A2 (pt) 2007-11-30 2007-11-30 "medicamento antimelancólico preparado com materiais à base de camp de jujuba"
PCT/CN2007/003397 WO2009070921A1 (fr) 2007-11-30 2007-11-30 Médicament antidépresseur à base de matériaux d'amp cylique de jujube
KR1020107011900A KR20100106324A (ko) 2007-11-30 2007-11-30 대추의 ｃＡＭＰ에 의해 제조되는 우울제
PT78457603T PT2221058E (pt) 2007-11-30 2007-11-30 Medicamento anti-melancolia preparado com materiais camp de jujuba
ZA2010/04032A ZA201004032B (en) 2007-11-30 2010-06-04 Antimelancholic medicine prepared with jujube camp materials
CY20131100749T CY1115223T1 (el) 2007-11-30 2013-08-29 Αντι-μελαγχολικο φαρμακο που παρασκευαζεται με υλικα camp απο τζιτζιφα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003397 WO2009070921A1 (fr) 2007-11-30 2007-11-30 Médicament antidépresseur à base de matériaux d'amp cylique de jujube

Publications (1)

Publication Number Publication Date
WO2009070921A1 true WO2009070921A1 (fr) 2009-06-11

Family

ID=40717254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003397 Ceased WO2009070921A1 (fr) 2007-11-30 2007-11-30 Médicament antidépresseur à base de matériaux d'amp cylique de jujube

Country Status (16)

Country Link
US (1) US8889650B2 (zh)
EP (1) EP2221058B1 (zh)
JP (1) JP2011504885A (zh)
KR (1) KR20100106324A (zh)
AU (1) AU2007362023B2 (zh)
BR (1) BRPI0722181A2 (zh)
CA (1) CA2707192C (zh)
CY (1) CY1115223T1 (zh)
DK (1) DK2221058T3 (zh)
ES (1) ES2426351T3 (zh)
MX (1) MX2010005838A (zh)
PL (1) PL2221058T3 (zh)
PT (1) PT2221058E (zh)
SI (1) SI2221058T1 (zh)
WO (1) WO2009070921A1 (zh)
ZA (1) ZA201004032B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100509006C (zh) 2005-03-25 2009-07-08 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法
CN102600070B (zh) * 2011-12-22 2014-08-27 湖北德康药业有限公司 环磷腺苷葡胺组合物注射液及其制备方法
CN104274323B (zh) * 2013-07-11 2019-05-17 天士力医药集团股份有限公司 液冷滴丸生产线
CN108152387A (zh) * 2017-11-22 2018-06-12 新疆农垦科学院 一种红枣中环磷酸腺苷的分析方法
CN110638825A (zh) * 2019-09-17 2020-01-03 中国药科大学 环磷酸腺苷、其衍生物或其前体药物在制备治疗抑郁症药物中的用途
CN116262772A (zh) * 2021-12-14 2023-06-16 无棣县华龙食品有限公司 一种水-醇双相萃取红枣渣中cAMP的方法
CN114591380B (zh) * 2022-04-20 2023-10-10 杨子萱 一种环磷腺苷的提取方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408257A (zh) * 2002-09-25 2003-04-09 河北农业大学 一种枣环核苷酸糖浆、膳食纤维和枣蜡的分离提取方法
CN1948329A (zh) * 2006-11-09 2007-04-18 常月梅 一种从枣中提取环磷酸腺苷的工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832631B2 (ja) * 1988-03-25 1996-03-29 株式会社ロッテ 精神安定用飲食物
JPH0761933A (ja) * 1993-08-25 1995-03-07 Earth Chem Corp Ltd 赤血球変形能の低下防止剤及び赤血球変形能の低下防止用補助食品
US6395311B2 (en) * 1998-04-29 2002-05-28 Univera Pharmaceuticals, Inc. Multicomponent biological vehicle
WO2004009557A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
CN100509006C (zh) * 2005-03-25 2009-07-08 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法
JP5313436B2 (ja) * 2006-03-23 2013-10-09 株式会社ナリス化粧品 メイラード反応阻害剤、それを含有する皮膚外用剤及び飲食品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408257A (zh) * 2002-09-25 2003-04-09 河北农业大学 一种枣环核苷酸糖浆、膳食纤维和枣蜡的分离提取方法
CN1948329A (zh) * 2006-11-09 2007-04-18 常月梅 一种从枣中提取环磷酸腺苷的工艺

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CH'UN-HSING CHANG: "Modern Psychology", WORLD HEALTH ORGANIZATION
See also references of EP2221058A4 *

Also Published As

Publication number Publication date
CY1115223T1 (el) 2017-01-04
EP2221058A4 (en) 2010-12-01
BRPI0722181A2 (pt) 2014-04-08
JP2011504885A (ja) 2011-02-17
EP2221058B1 (en) 2013-05-29
US8889650B2 (en) 2014-11-18
CA2707192A1 (en) 2009-06-11
ZA201004032B (en) 2011-03-30
HK1147676A1 (zh) 2011-08-19
MX2010005838A (es) 2010-09-14
AU2007362023A1 (en) 2009-06-11
AU2007362023B2 (en) 2012-04-19
EP2221058A1 (en) 2010-08-25
ES2426351T3 (es) 2013-10-22
CA2707192C (en) 2015-06-02
SI2221058T1 (sl) 2013-11-29
PT2221058E (pt) 2013-08-30
US20100311682A1 (en) 2010-12-09
DK2221058T3 (da) 2013-09-02
PL2221058T3 (pl) 2013-11-29
KR20100106324A (ko) 2010-10-01

Similar Documents

Publication Publication Date Title
WO2009070921A1 (fr) Médicament antidépresseur à base de matériaux d&#39;amp cylique de jujube
WO2009070915A1 (fr) Compositions pharmaceutiques destinées à traiter la dépression et l&#39;anxiété
RU2395293C2 (ru) Фармацевтическая композиция для лечения депрессии и способ ее получения
JP5628682B2 (ja) 鬱病治療のための薬剤組成物
WO2009070922A1 (en) Pharmaceutical compositions for treating anxiety
TWI453027B (zh) 主功效成分為大棗環腺苷單磷酸之藥物作為治療憂鬱症的用途
CN108542898A (zh) 木豆素及其组合物在制备治疗抑郁症药物中的用途
TWI394576B (zh) 以人參、大棗為原料的治療憂鬱症的藥物組合物及其製法
CN101450070A (zh) 以大枣cAMP为原料制成的抗忧郁药物
CN101450063A (zh) 治疗忧郁症的口服药物
WO2009070923A1 (en) A pharmaceutical composition for treating melancholy and preparation method thereof
CN101450120A (zh) 以人参、大枣为原料的治疗忧郁症的药物组合物及其制备方法
RU2456014C2 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО ОТ МЕЛАНХОЛИИ, ПОЛУЧЕННОЕ С ИСПОЛЬЗОВАНИЕМ МАТЕРИАЛОВ С сАМР ЖУЖУБА
TWI400078B (zh) 以甘草、大棗為原料的治療憂鬱症的藥物組合物
CN101450121A (zh) 以甘草、大枣为原料的治疗忧郁症的药物组合物及其制法
WO2009070917A1 (en) An oral pharmaceutical composition for treating barythymia
CN110279738A (zh) 一种抗抑郁的亚精胺有效部位的提取方法及亚精胺有效部位提取物的用途
CN1686514A (zh) 治疗焦虑症、抑郁症的中药制剂及其生产方法
TW202011832A (zh) 一種可使體溫上升以預防疾病的複方營養保健品
CN101450062A (zh) 多靶标受体后作用机制用于治疗忧郁症的药物组合物
WO2009070916A1 (fr) Composition pharmaceutique pour le traitement de la dépression et son procédé de préparation
TWI436772B (zh) Pharmaceutical compositions for the manufacture of pharmaceutical compositions for the treatment of anxiety disorders
TWI364287B (zh)
TW200920391A (en) Multi-target post-receptor action used in pharmaceutical composition for depression treatment
CN114668148A (zh) 具有安神助眠功效的保健组合物及其制备方法、保健品和应用

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845760

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1926/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/005838

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20107011900

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2707192

Country of ref document: CA

Ref document number: 12010501243

Country of ref document: PH

Ref document number: 2007845760

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010535191

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007362023

Country of ref document: AU

Date of ref document: 20071130

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010121519

Country of ref document: RU

Ref document number: 10079500

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PI 2010002480

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12745438

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0722181

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100531